The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
CXCR7/CXCR4 Heterodimer Constitutively Recruits β-Arrestin to Enhance Cell Migration
Open accessAbstract
G protein-coupled receptor hetero-oligomerization is emerging as an important regulator of ligand-dependent transmembrane signaling, but precisely how receptor heteromers affect receptor pharmacology remains largely unknown. In this study, we have attempted to identify the functional significance of the heteromeric complex between CXCR4 and CXCR7 chemokine receptors. We demonstrate that co-expression of CXCR7 with CXCR4 results in constitutive recruitment of β-arrestin to the CXCR4·CXCR7 complex and simultaneous impairment of Gi-mediated signaling. CXCR7/CXCR4 co-expression also results in potentiation of CXCL12 (SDF-1)-mediated downstream β-arrestin-dependent cell signaling pathways, including ERK1/2, p38 MAPK, and SAPK as judged from the results of experiments using siRNA knockdown to deplete β-arrestin. Interestingly, CXCR7/CXCR4 co-expression enhances cell migration in response to CXCL12 stimulation. Again, inhibition of β-arrestin using either siRNA knockdown or a dominant negative mutant abrogates the enhanced CXCL12-dependent migration of CXCR4/CXCR7-expressing cells. These results show how CXCR7, which cannot signal directly through G protein-linked pathways, can nevertheless affect cellular signaling networks by forming a heteromeric complex with CXCR4. The CXCR4·CXCR7 heterodimer complex recruits β-arrestin, resulting in preferential activation of β-arrestin-linked signaling pathways over canonical G protein pathways. CXCL12-dependent signaling of CXCR4 and its role in cellular physiology, including cancer metastasis, should be evaluated in the context of potential functional hetero-oligomerization with CXCR7. G protein-coupled receptor hetero-oligomerization is emerging as an important regulator of ligand-dependent transmembrane signaling, but precisely how receptor heteromers affect receptor pharmacology remains largely unknown. In this study, we have attempted to identify the functional significance of the heteromeric complex between CXCR4 and CXCR7 chemokine receptors. We demonstrate that co-expression of CXCR7 with CXCR4 results in constitutive recruitment of β-arrestin to the CXCR4·CXCR7 complex and simultaneous impairment of Gi-mediated signaling. CXCR7/CXCR4 co-expression also results in potentiation of CXCL12 (SDF-1)-mediated downstream β-arrestin-dependent cell signaling pathways, including ERK1/2, p38 MAPK, and SAPK as judged from the results of experiments using siRNA knockdown to deplete β-arrestin. Interestingly, CXCR7/CXCR4 co-expression enhances cell migration in response to CXCL12 stimulation. Again, inhibition of β-arrestin using either siRNA knockdown or a dominant negative mutant abrogates the enhanced CXCL12-dependent migration of CXCR4/CXCR7-expressing cells. These results show how CXCR7, which cannot signal directly through G protein-linked pathways, can nevertheless affect cellular signaling networks by forming a heteromeric complex with CXCR4. The CXCR4·CXCR7 heterodimer complex recruits β-arrestin, resulting in preferential activation of β-arrestin-linked signaling pathways over canonical G protein pathways. CXCL12-dependent signaling of CXCR4 and its role in cellular physiology, including cancer metastasis, should be evaluated in the context of potential functional hetero-oligomerization with CXCR7.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
The Role of CXCR7/RDC1 as a Chemokine Receptor for CXCL12/SDF-1 in Prostate Cancer
Wang, J., Shiozawa, Y., Wang, J., Wang, Y., Jung, Y., Pienta, K. J., Mehra, R., Loberg, R., & Taichman, R. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707465200 · Cited by 457
RetractedInvolvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors
Murphy, P. M., Baggiolini, M., Charo, I. F., Hébert, C. A., Horuk, R., Matsushima, K., Miller, L. H., Oppenheim, J. J., & Power, C. A. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01439-x · Cited by 1,817
Transduction of Receptor Signals by ß-Arrestins
Lefkowitz, R. J., & Shenoy, S. K. (2005) · Science · doi:10.1126/science.1109237 · Cited by 1,727
Dependence of Human Stem Cell Engraftment and Repopulation of NOD/SCID Mice on CXCR4
Peled, A., Petit, I., Kollet, O., Magid, M., Ponomaryov, T., Byk, T., Nagler, A., Ben-Hur, H., Many, A., Shultz, L., et al. (1999) · Science · doi:10.1126/science.283.5403.845 · Cited by 1,644
β-Arrestin-Dependent Formation of β 2 Adrenergic Receptor-Src Protein Kinase Complexes
Luttrell, L. M., Ferguson, S. S. G., Daaka, Y., Miller, W. E., Maudsley, S., Della Rocca, G. J., Lin, F.-T., Kawakatsu, H., Owada, K., Luttrell, D. K., et al. (1999) · Science · doi:10.1126/science.283.5402.655 · Cited by 1,475
Burns, J. M., Summers, B. C., Wang, Y., Melikian, A., Berahovich, R., Miao, Z., Penfold, M. E. T., Sunshine, M. J., Littman, D. R., Kuo, C. J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052144 · Cited by 1,263
The Chemokine SDF-1/CXCL12 Binds to and Signals through the Orphan Receptor RDC1 in T Lymphocytes
Balabanian, K., Lagane, B., Infantino, S., Chow, K. Y. C., Harriague, J., Moepps, B., Arenzana-Seisdedos, F., Thelen, M., & Bachelerie, F. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508234200 · Cited by 1,040
Role of β-Arrestin in Mediating Agonist-Promoted G Protein-Coupled Receptor Internalization
Ferguson, S. S. G., Downey, W. E., Colapietro, A.-M., Barak, L. S., Ménard, L., & Caron, M. G. (1996) · Science · doi:10.1126/science.271.5247.363 · Cited by 972
Chemokine receptors: multifaceted therapeutic targets
Proudfoot, A. E. I. (2002) · Nature Reviews Immunology · doi:10.1038/nri722 · Cited by 752
Cited by
Bachelerie, F., Ben-Baruch, A., Burkhardt, A. M., Combadiere, C., Farber, J. M., Graham, G. J., Horuk, R., Sparre-Ulrich, A. H., Locati, M., Luster, A. D., et al. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.007724 · Cited by 850
Biased signalling: from simple switches to allosteric microprocessors
Smith, J. S., Lefkowitz, R. J., & Rajagopal, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.229 · Cited by 738
Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis
Ding, B.-S., Cao, Z., Lis, R., Nolan, D. J., Guo, P., Simons, M., Penfold, M. E., Shido, K., Rabbany, S. Y., & Rafii, S. (2014) · Nature · doi:10.1038/nature12681 · Cited by 626
Immune regulation by atypical chemokine receptors
Nibbs, R. J. B., & Graham, G. J. (2013) · Nature Reviews Immunology · doi:10.1038/nri3544 · Cited by 407
The unique structural and functional features of CXCL12
Janssens, R., Struyf, S., & Proost, P. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.107 · Cited by 378
The Chemokine Receptor CXCR4 in Cell Proliferation and Tissue Regeneration
Bianchi, M. E., & Mezzapelle, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02109 · Cited by 335
The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease
Döring, Y., Pawig, L., Weber, C., & Noels, H. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00212 · Cited by 289
Cao, Z., Lis, R., Ginsberg, M., Chavez, D., Shido, K., Rabbany, S. Y., Fong, G.-H., Sakmar, T. P., Rafii, S., & Ding, B.-S. (2016) · Nature Medicine · doi:10.1038/nm.4035 · Cited by 285
Self-citationTargeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Zhou, W., Guo, S., Liu, M., Burow, M. E., & Wang, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170830111531 · Cited by 278
Klos, A., Wende, E., Wareham, K. J., & Monk, P. N. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005223 · Cited by 264
G protein-coupled receptor heteromers
Gomes, I., Ayoub, M. A., Fujita, W., Jaeger, W. C., Pfleger, K. D. G., & Devi, L. A. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135952 · Cited by 262
CXCR4 signaling in health and disease
Pozzobon, T., Goldoni, G., Viola, A., & Molon, B. (2016) · Immunology Letters · doi:10.1016/j.imlet.2016.06.006 · Cited by 256
Emerging targets in cancer management: role of the CXCL12/CXCR4 axis
Dubrovska, A., Cojoc, M., Peitzsch, Trautmann, F., Polishchuk, & Telegeev (2013) · OncoTargets and Therapy · doi:10.2147/ott.s36109 · Cited by 254
Metadata
- Authors
- Décaillot, F. M., Kazmi, M. A., Lin, Y., Ray-Saha, S., Sakmar, T. P., & Sachdev, P.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2011-09
- Volume
- 286
- Issue
- 37
- Pages
- 32188-32197
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2035832696
- Cited by
- 333
- References
- 62
- FWCI
- 12.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.